Discover shows related to The Biotech Voyager, based on actual content similarities. Explore podcasts with similar topics, themes, and formats, backed by real data.
There is no related content for this show.
No links shared by this podcast
RSS feed quality
To improve
Score global : 43%
BigHat Raises $75M, a Parkinson’s Vaccine & Engineered Red Blood Cells
Saturday, September 26, 2026 • Duration 01:40:19
Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news.
Hosted by Benjamin McLeod and Jeff Martin, PhD.
In this episode, the hosts navigate an exceptionally busy day in biotech, examining multiple groundbreaking signals across diverse therapeutic modalities and emerging technologies. From AI-powered antibody discovery to neutrophil cell therapies, the conversation spans cutting-edge innovation while maintaining critical scientific scrutiny.
The episode opens with Big Hat Biosciences' impressive $75 million Series C raise, examining their AI-driven platform for antibody drug conjugate development. The hosts explore how Big Hat's cyclical approach integrates automated wet lab experimentation with AI analysis to iteratively improve therapeutic candidates. The discussion contextualizes AI's role in drug discovery, distinguishing between AI for molecular design versus AI for data analysis and experimental optimization. With backing from major pharmaceutical companies including Amgen, BMS, Eli Lilly, and Merck, and fresh patient dosing in Phase I trials, Big Hat represents a significant validation signal for AI-enabled therapeutic development.
The conversation continues with Basecamp Research's massive $140 million Series C, exploring their Eden AI model trained on 9.7 trillion nucleotide tokens from ethically sourced genomic data across 30+ countries. The hosts examine how this comprehensive genetic diversity dataset could enable more effective in vivo CAR-T therapies for solid tumors by identifying candidates with broader patient population applicability. The discussion probes the technical challenges of translating genomic data into functional therapeutics while acknowledging the ambitious nature of in vivo cell therapy approaches.
Additional signals include AvenCell's $47 million raise for their universal switchable CAR-T platform, which achieved 71% overall response rates in relapsed/refractory AML using adapter molecules that can target multiple antigens. The hosts examine Scarlet Therapeutics' DARPA-funded program developing smart red blood cells that sense environmental conditions and deliver therapeutics accordingly. Lyft Therapeutics emerges from rebranding with neutrophil cell therapies, though the hosts express significant skepticism about the six to twelve hour lifespan challenge inherent to neutrophil-based therapeutics. AC Immune's active immunotherapy for Parkinson's demonstrates 100% antibody response rates at 100 weeks, prompting debate about terminology distinctions between vaccines and active immunotherapies.
The episode features an interview with Ryan from LabThread discussing laboratory software challenges and the future of lab automation, followed by examination of Anthropic's Claude-led discovery of a potential new gene editing mechanism and the A16Z Academy as an alternative to traditional university education for aspiring biotech professionals.
Listeners will gain insight into how AI is transforming both therapeutic development and laboratory operations, the critical importance of therapeutic lifespan in cell therapy design, the evolving role of government funding through programs like DARPA and ARPA-H, and why the distinction between prophylactic vaccines and therapeutic active immunotherapies matters for understanding emerging modalities.
New episodes every Tuesday and Thursday at 11:00 AM.
#biotech #AI #drugdiscovery #CARTtherapy #genetherapy #antibodies #celltherapy #activeimmunotherapy #labautomation
100% Response Rate in ALL: Vironexis's Gene Therapy T-Cell Engager (But There's a Catch)
Friday, September 25, 2026 • Duration 01:17:22
Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news.
Hosted by Benjamin McLeod and Jeff Martin, PhD.
In this episode, the hosts navigate an exceptionally busy day in biotech, examining multiple groundbreaking signals across diverse therapeutic modalities. From gene therapies that transform the liver into drug factories to innovative biomaterials that dissolve over time, the conversation spans the cutting edge of biotechnology innovation.
The episode opens with an in-depth analysis of ViroNexus, a company developing a revolutionary AAV-based gene therapy for acute lymphoblastic leukemia. Rather than infusing T-cell engagers directly, ViroNexus delivers a transgene that transforms hepatocytes into factories that continuously produce and secrete these therapeutics into the bloodstream. The hosts examine the striking 100% response rate at nine months in three patients, while carefully contextualizing both the promise and significant questions surrounding this biofactory approach. The discussion explores a critical challenge: how do you turn off a therapeutic that's designed to produce drugs for years when targeting healthy B cells could lead to prolonged immunosuppression?
The conversation moves through Acro Biosciences' selective RIPK2 inhibitor for ulcerative colitis, examining how targeted inhibition of inflammatory signaling cascades offers straightforward solutions to complex diseases. The hosts then explore Biactica's non-PROTAC oral protein degrader for glioblastoma, highlighting how this orally bioavailable, blood-brain barrier-crossing therapeutic represents a new frontier in targeting previously undruggable proteins through degradation rather than inhibition.
Additional signals include Anixa's dual approach combining cancer vaccines with chimeric endocrine receptor therapy for breast cancer, Dualitas' bispecific antibodies that achieve synergistic effects by targeting proximal cell surface proteins, and Dialibrid's innovative silk-polyurethane biomaterial that provides structural support for cell therapies before dissolving over time. The episode concludes with a paper of the day segment examining dual-targeted CAR-T approaches for glioblastoma that simultaneously eliminate both tumor cells and the immunosuppressive myeloid shield.
Listeners will gain insight into the promise and challenges of biofactory therapeutics, the expanding toolkit of protein degradation technologies, the importance of controllable expression systems in gene therapy, and why targeting the tumor microenvironment may be as critical as targeting cancer cells themselves.
New episodes every Tuesday and Thursday at 11:00 AM.
#biotech #genetherapy #proteindegraders #glioblastoma #bispecificantibodies #biomaterials #celltherapy
100% Response Rate at Nine Months: Revolutionary Cell Therapy Shows Promise
Friday, September 25, 2026 • Duration 01:02
Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news.
Hosted by Benjamin McLeod and Jeff Martin, PhD.
In this episode, the hosts examine a striking clinical trial result that has generated significant attention in the cell therapy and oncology communities. The discussion centers on a therapeutic approach that has achieved a 100% response rate at nine months in early patient data, a result that stands out dramatically even in a field that has seen remarkable advances in recent years.
The conversation explores both the promise and the important caveats surrounding this data. While a 100% response rate represents an extraordinary outcome compared to existing therapies where 70% response rates are considered exceptional, the hosts carefully contextualize this finding within the reality of early clinical development. The result comes from just three patients, making it a preliminary signal rather than definitive proof of efficacy. The discussion examines what constitutes meaningful evidence in early-stage trials and how to interpret small patient cohorts while maintaining appropriate scientific skepticism.
The episode delves into the durability aspect of these responses, with patients showing sustained therapeutic benefit out to approximately 260 days following a single infusion. This durability is particularly noteworthy in the context of cell-based therapies, where persistence and long-term function remain critical challenges. The hosts also note the favorable safety profile, with no dose limiting toxicities observed in these initial patients, though questions remain about longer-term follow-up and broader patient populations.
Listeners will gain insight into how to evaluate early-stage clinical data in cell therapy, the significance of response rates and durability in assessing therapeutic potential, and why promising preliminary results require careful interpretation before drawing definitive conclusions about clinical impact.
New episodes every Tuesday and Thursday at 11:00 AM.
#biotech #celltherapy #clinicaltrials #oncology #immunotherapy #durability
Big Picture Bio's AI Model: Predicting Drug Combinations to Triple Cancer Survival
Tuesday, September 22, 2026 • Duration 01:23
Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news.
Hosted by Benjamin McLeod and Jeff Martin, PhD.
In this episode, the hosts dive deep into an innovative approach to cancer treatment that combines AI-driven drug discovery with population-level tumor modeling. The conversation explores how computational platforms are being used to identify novel drug combinations that could dramatically extend overall survival in cancer patients.
The discussion centers on a groundbreaking methodology that tests hypotheses using AI to generate drug candidates, followed by synthesis and wet lab validation. This approach bridges both drug repurposing of approved combinations and the discovery of entirely new therapeutic strategies. The guest reveals an ambitious vision: extending overall survival by potentially three times through cleverly combined existing drugs and novel approaches.
The episode examines the technical sophistication behind population-level cancer modeling, including the use of Mueller plots to visualize which tumor cell populations get eliminated and which resistant populations emerge over time. This granular view reveals both the promise and the challenge: while initial combinations can knock out 90% of tumor bulk, persistent resistant populations present an even greater therapeutic challenge. The conversation explores why achieving complete cancer resolution may require going beyond existing drugs to develop truly novel approaches.
Listeners will gain insight into how AI and computational biology are transforming cancer drug development, the strategic balance between drug repurposing and novel discovery, and why understanding tumor population dynamics at high resolution is critical for developing next-generation combination therapies.
New episodes every Tuesday and Thursday at 11:00 AM.
#biotech #AI #drugdiscovery #cancer #combinationtherapy #computationalbiology
CRISPR Stealth Organs: Deleting HLA to Prevent Transplant Rejection
Tuesday, September 22, 2026 • Duration 00:43
Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news.
Hosted by Benjamin McLeod and Jeff Martin, PhD.
In this episode, the hosts explore a revolutionary approach to organ transplantation that could fundamentally transform how we think about tissue rejection and donor compatibility. The discussion centers on an innovative gene therapy technique that modifies donor organs before transplantation by removing the molecular markers that trigger immune rejection.
The conversation examines the science behind HLA deletion, the key recognition system that T cells use to identify foreign tissue. The hosts walk through the technical process of soaking donor organs in viral mixtures containing CRISPR-based gene therapies designed to eliminate HLA markers from the organ surface. This approach creates what could be described as a "stealth organ" that evades immune detection, potentially eliminating the need for lifelong immunosuppression in transplant recipients.
The episode delves into the implications of this technology for critical organs including hearts, livers, and kidneys. By removing the molecular signatures that distinguish one person's tissue from another, this approach could dramatically expand the donor pool and reduce transplant rejection rates. The discussion explores how gene editing technologies like CRISPR are being applied not just to individual cells but to entire organs, representing a significant leap in the practical application of gene therapy.
Listeners will gain insight into how cutting-edge gene editing is being deployed to solve one of transplant medicine's most persistent challenges, the technical mechanisms behind immune recognition and evasion, and the potential for this approach to reshape organ transplantation in the coming years.
New episodes every Tuesday and Thursday at 11:00 AM.
#biotech #CRISPR #organtransplantation #genetherapy #immunology #HLA
Big Picture Bio emerges from Stealth! World Models for Combination Therapies
Thursday, September 17, 2026 • Duration 13:36
Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before they're big news.
AI for Cell Therapy is Heating Up (Innovator Session)
Wednesday, September 16, 2026 • Duration 01:33:24
Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news.
Hosted by Benjamin McLeod and Jeff Martin, PhD.
Scar Tissue Is Blocking Paralyzed Patients
Saturday, September 12, 2026 • Duration 01:07
Hundreds of Millions in New Funding! Is Biotech BACK?
Friday, September 11, 2026 • Duration 01:16:21
Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news.
Hosted by Benjamin McLeod and Jeff Martin, PhD.
Matricelf's Cell Therapy for Spinal Cord Injury, and the Continued Ascendance of mRNA-LNP
Wednesday, September 2, 2026 • Duration 01:34:23
Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news.
Hosted by Benjamin McLeod and Jeff Martin, PhD.
